TAMRINTAMAB PAMOZIRINE
UNII GM0RU5SU0E

Substance Identification & Data

This profile provides standardized clinical and technical data for Tamrintamab Pamozirine, uniquely identified by the FDA Unique Ingredient Identifier (UNII) GM0RU5SU0E.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2148334-68-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
GM0RU5SU0E
CAS Registry Number
2148334-68-1
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
TAMRINTAMAB PAMOZIRINE
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C124133
National Cancer Institute reference terminology for clinical and research data.
INN ID
10961
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
protein
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tamrintamab Pamozirine. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TAMRINTAMAB PAMOZIRINE

Common Names & Synonyms

TAMRINTAMAB PAMOZIRINE [INN]

Systematic Nomenclature

IMMUNOGLOBULIN G1(226-SERINE), ANTI-(HUMAN DIPEPTIDASE 3)(HUMAN-MUS MUSCULUS MONOCLONAL SC34.28SS1 .GAMMA.1-CHAIN), COMPD. WITH HUMAN-MUS MUSCULUSMONOCLONAL SC34.28SS1 .KAPPA.-CHAIN, DIMER, BIS(THIOETHER) WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)-L-VALYL-N-(4-(((((11S,11S)-8-((5-(((11AS)-5,11A-DIHYDRO-7-METHOXY-2-METHYL-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-8-YL)OXY)PENTYL)OXY)-11,11A-DIHYDRO-11-HYDROXY-7-METHOXY-2-METHYL-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-10(5H)-YL)CARBONYL)OXY)METHYL)PHENYL)-L-ALANINAMIDE
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS DPEP3 (DIPEPTIDASE 3)), HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO A PYRROLOBENZODIAZEPINE DIMER (PBD) SC-DR002 AT CYS215' AND CYS215'''GAMMA1 HEAVY CHAIN HUMANIZED (1-452) (VH (HOMO SAPIENS IGHV1-69*01 (85.7%)-(IGHD)-IGHJ6*01 (90.9%)) (8.8.16) (1-123)-HOMO SAPIENS IGHG1*01, G1M17,1 (CH1 K120 (220) (124-221), HINGE C5>S (226) (222-236), CH2 (237-346), CH3 D12 (362), L14 (364) (347-451), CHS K>DEL (452)) (124-452)), NON-COVALENTLY ASSOCIATED WITH KAPPA LIGHT CHAIN HUMANIZED (1'-215') (V-KAPPA (HOMO SAPIENS IGKV3D-20*01 (86.50%)-IGKJ2*01 (100.0%)) (7.3.9) (1'-108'),-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (154), V101 (192) (109'-215'))DIMER (232-232'':235-235'')-BISDISULFIDECONJUGATED AT EACH CL C126 (215', 215''') TO A PYRROLOBENZODIAZEPINE DIMER (PBD) SC-DR002 VIA A PROTEASE-CLEAVABLE MALEIMIDE LINKER (LD6.23)

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus